Lumos Pharma Past Earnings Performance
Past criteria checks 0/6
Lumos Pharma's earnings have been declining at an average annual rate of -28.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 73.4% per year.
Key information
-28.8%
Earnings growth rate
-29.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 73.4% |
| Return on equity | -124.6% |
| Net Margin | -1,659.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
Aug 25
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?
Mar 13Lumos Pharma announces new buyback program
Aug 16Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Mar 22Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth
Nov 04What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?
Dec 09Lumos Pharma (LUMO) Investor Presentation - Slideshow
Nov 17Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 11Revenue & Expenses BreakdownBeta
How Lumos Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -34 | 17 | 22 |
| 30 Sep 23 | 2 | -33 | 17 | 20 |
| 30 Jun 23 | 2 | -32 | 17 | 19 |
| 31 Mar 23 | 2 | -31 | 16 | 18 |
| 31 Dec 22 | 2 | -31 | 16 | 18 |
| 30 Sep 22 | 1 | -28 | 16 | 16 |
| 30 Jun 22 | 1 | -29 | 14 | 16 |
| 31 Mar 22 | 0 | -30 | 15 | 16 |
| 31 Dec 21 | 0 | -30 | 15 | 16 |
| 30 Sep 21 | 0 | -27 | 15 | 15 |
| 30 Jun 21 | 0 | -18 | 18 | 13 |
| 31 Mar 21 | 0 | -15 | 18 | 12 |
| 31 Dec 20 | 0 | -6 | 17 | 9 |
| 30 Sep 20 | 0 | -7 | 14 | 8 |
| 30 Jun 20 | 0 | -12 | 10 | 7 |
| 31 Mar 20 | 0 | -10 | 7 | 6 |
| 31 Dec 19 | 0 | -13 | 4 | 6 |
| 30 Sep 19 | 0 | -11 | 4 | 6 |
| 31 Dec 18 | 0 | -11 | 3 | 5 |
Quality Earnings: LUMO is currently unprofitable.
Growing Profit Margin: LUMO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LUMO is unprofitable, and losses have increased over the past 5 years at a rate of 28.8% per year.
Accelerating Growth: Unable to compare LUMO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LUMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: LUMO has a negative Return on Equity (-124.64%), as it is currently unprofitable.